The article discusses on stromal-directed therapeutics for cancer. It states that the said approach was tested in mouse models and in clinical trials, and has begun transstion to clinical usage. It mentions two examples of drugs which targets cancer microenvironment, such as the bevacizumab and zoledronic acid. It also mentions several emerging medicators of cancer-stroma crosstalk, which include fibroblast activation protein, interleukin-6, and chemokines.